FDA warns Cordis over Cypher stents; may delay approval of catheter
This article was originally published in Clinica
Executive Summary
Johnson & Johnson’s cardiovascular unit Cordis could face further disruption to the supply of its Cypher stent following an FDA warning letter concerning violations found at the Puerto Rico facility that manufactures the devices.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.